On the stock market since 2021, it operates in the world of health and science. It has 39 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly below the class average.
Clearly below the class average.
Growth: Sales growth trails the sector average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 65% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
There is $208.9M in the vault; even if every debt were paid off, $199.1M would remain.
Over the last 12 months, company executives reported 23 buys and 5 sells. Management buying with its own money is usually read as a good sign.
The average analyst price target is $7.50 — 218% above today’s price.
A loss of $66.5M against $0 in annual sales. And on top of that, sales fell from the year before.
The growth engine is running at low revs right now. Report-card grade: 16/100.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 26/100. For a turnaround signal, the stock first needs to close the gap with the market.
On our five-subject report card, CMPX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: CMPX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (38/100) says the stock isn’t cheap.